Pyxis Oncology, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Pyxis Oncology, Inc. (PYXS) is a clinical-stage biotechnology company that develops antibody-drug conjugates and immunotherapies targeting difficult-to-treat solid tumors. The company offers a pipeline of product candidates including PYX-201, a lead investigational ADC comprising human immunoglobulin G1 targeting extradomain-B fibronectin in Phase 1 trials for relapsed or refractory solid tumors such as head and neck squamous cell carcinoma; PYX-106, a Siglec-15-targeting monoclonal antibody in Phase 1 for advanced solid tumors; PYX-107, a CD40 agonist monoclonal antibody in Phase 2 for soft tissue sarcomas, esophageal and gastroesophageal junction cancers, and pancreatic ductal adenocarcinoma; PYX-203, an ADC licensed from Pfizer Inc.; and additional candidates leveraging its proprietary Flexible Antibody Conjugation Technology platform combined with the APXiMAB antibody-discovery platform. Pyxis Oncology, founded in 2018 and headquartered in Boston, Massachusetts, operates primarily in the United States with a focus on oncology therapeutics for patients with advanced cancers. Recent strategic developments include the 2023 acquisition of Apexigen, adding a validated Phase 2-ready antibody platform and expanding ADC capabilities while maintaining cash runway into 2026; in-licensing deals with Pfizer for ADC candidates like PYX-201 and PYX-203, and with Biosion USA for PYX-106; positive November 2024 Phase 1 data for PYX-201 showing 50% objective response rate in head and neck squamous cell carcinoma; and December 2024 portfolio prioritization to focus resources on PYX-201 monotherapy and combination trials, including with Keytruda in front-line settings, while deprioritizing PYX-106.
Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones
Pyxis Oncology to Participate in Upcoming Investor Conferences
Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer
Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026
Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Pyxis Oncology (PYXS) Projected to Post Quarterly Earnings on Tuesday
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Rating of “Moderate Buy” by Brokerages
Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity
Pyxis Oncology, Inc. (NASDAQ:PYXS) Short Interest Update
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Analysts Sound Alarm On Pyxis Oncology's Tiny Trial
Pyxis Oncology, Inc. (PYXS) Discusses Preliminary Phase 1 Data for MICVO in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma Transcript
Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Pyxis Oncology to Participate in Upcoming Investor Conferences
Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results
Pyxis Oncology (PYXS) Upgraded to Strong Buy: Here's What You Should Know
5 Small Drug Stocks to Buy as the Industry Shows Some Recovery
Pyxis Oncology to Present Translational Data and Key Biology Findings Elucidating the Mechanism of Action of MICVO at Upcoming Medical Meetings
Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)